Card image cap
Cantex to repurpose Wyss Institute drug for lung diseases

Cantex Pharmaceuticals, a Weston-based drug maker, said that it plans to develop  azeliragon, a small-molecule drug identified by Harvard’s Wyss Institute, for the treatment of inflammatory lung diseases including COVID-19. The company said that it has  secured a global licence from Harvard University’s Office of Technology Development (OTD) after the drug exhibited significant reduction in the production of inflammation-causing cytokines including IL-6, IL-8, and IP-10 as well as RANTES, a key proinflammatory cytokine produced by virus-infected lung cells, following viral infection. The company pointed out that previous clinical trials of the drug had also demonstrated a high level of safety in Phase 3 clinical trials involving over 2,000 patients, for Alzheimer’s Disease. Cantex also revealed its plans to initiate Phase 2 clinical trials exploring azeliragon in pancreatic and breast cancers

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment